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Abstract
Purpose: This study describes the long-term visual and anatomic outcomes of anti-
vascular endothelial growth factor (VEGF) treatment using a treat and extend dosing
regimen.
Methods: This cross-sectional cohort study consisted of 224 treatment-naïve eyes with
neovascular age-related macular degeneration (NV-AMD) from 202 patients that were
treated with anti-VEGF agents bevacizumab, ranibizumab, and aflibercept using a treat
and extend (TAE) regimen by four physician investigators in a large urban referral center
from 2008 to 2015. Subjects were evaluated for visual acuity, injection frequency, and
optical coherence tomography (OCT).
Results: Over a seven-year follow-up period (mean 3.4 years), an average 20.2 ± 14.7
injections were administered with 8.4 injections in the first year and 5.5 injections by the
seventh year of remaining eyes undergoing treatment. Visual acuity was 0.70 logMAR
(20/100 Snellen) at the first visit and 0.67 logMAR (20/93 Snellen) at the final visit, with
74% of eyes maintaining or gaining more than 2 lines of vision. Long-term, 45.1% of eyes
achieved 20/50 or better, while 27.1% were 20/200 or worse. Of the treated patients,
61.2% received monotherapy with no difference in visual acuity outcomes or number of
injections between the agents used. OCT analysis showed decreased fluid from initial
to final follow-up visit: 70.1–15.6% with sub-retinal fluid (SRF) and 47.3–18.8% with intra-
retinal fluid (IRF) with no difference between the agents were used.
Conclusion: This study demonstrates that most patients (74%) improve or maintain visual
acuity long-term using a TAE model with a significant portion (45.1%) achieving 20/50 or
better visual acuity with sustained treatment.
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Neovascular age-related macular degeneration
(NV-AMD) is the leading cause of vision loss in
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individuals aged 50 years or older. Over the past
decade, treatment has evolved to control subfoveal
choroidal neovascularization (CNV) growth with
intravitreal drug delivery directed toward inhibition
of vascular endothelial growth factor (VEGF).
Specifically, the MARINA and ANCHOR studies
were amongst the first to demonstrate the effects
of targeting angiogenesis by blocking VEGF-A
with ranibizumab, a recombinant humanized
monoclonal antibody fragment (Fab). These
studies clearly showed that monthly treatment
was beneficial in preventing vision loss and
allowing for visual gain compared to sham and
photodynamic therapy (PDT), respectively, over
a two-year period.[1–3] The VIEW 1 and 2 trials
demonstrated the efficacy of aflibercept, a soluble
decoy receptor fusion protein with a higher affinity
to VEGF-A and VEGF-B as well as placental
growth factor (PIGF) with decreased treatment
burden allowing improvement or maintenance of
vision over two years.[4, 5] However, monthly or
bimonthly injections along with monthly follow-up
is challenging for patients to maintain in clinical
practice.
Due to treatment burden, pro re nata (PRN)
treatment was studied to examine the effects
of monthly follow-up with an individualized
retreatment regimen. CATT and IVAN trials
demonstrated equivalent efficacy between
ranibizumab versus bevacizumab; however,
there was an overall less favorable outcome in
the PRN arms compared to monthly dosing with
respect to final visual acuity.[6–8]
In 2009, Freund and colleagues were the first
to describe the “treat-and-extend (TAE)” regimen
with treatment of Type 3 CNV lesions in a small
cohort over three years.[9] With use of ranibizumab
and/or bevacizumab, they showed an overall
improvement of vision from 20/80 to 20/40 with
an average of 6–7 injections per year. Since then,
several other retrospective studies have proposed
using a TAE approach as an alternate to monthly
or PRN dosing to reduce treatment burden while
maintaining or improving visual outcome.[10–12]
Despite the multitude of trials demonstrating
the safety and efficacy of anti-VEGF drug therapy,
there have been limited studies describing the
long-term follow-up of anti-VEGF treatment.
SEVEN-UP and CATT were among the first studies
to describe the long-term outcomes with either
monthly or PRN dosing.[13, 14] Of the TAE trials, the
longest to date was by Mrejen et al over a six-year
period with 185 patients and a retention rate of
62.9%.[12] Their study showed an improvement or
maintenance in visual acuity with an average of
8.3 injections per year. They demonstrated that a
greater number of injections was an independent
predictor of better visual outcome. Other studies
have compared TAE to PRN revealing a worse
visual outcome with a smaller number of injections
with the PRN group.[15, 16] Specifically, Calvo et al
showed that over a three-year follow-up period,
42.4% in the TAE dosing group versus 24.1% in
the PRN dosing group gained at least three lines
of vision. Over the study period, the TAE group
was treated with an average of 20.31 injections,
while the PRN group was treated with an average
of 18.41.[15] TAE is a practical option to reducing the
number of injections and office visits as compared
to a monthly and PRN regimen.
Our current study reports a seven-year follow-
up period of the long-term outcomes as measured
by visual acuity and OCT imaging of the treatment-
naïve NV-AMD patients using a TAE model.
METHODS
The Institutional Review Board of Northwestern
University Feinberg School of Medicine approved
this retrospective cohort study at a large urban
tertiary medical center. Study data was obtained
through the Northwestern Medicine Enterprise
Data Warehouse (NMEDW) and through direct
chart review. Our study population consisted of
treatment-naïve patients of four retina specialists
receiving intravitreal anti-VEGF with the diagnosis
of neovascular AMD (ICD-9 code 362.52) from
March 2008 to October 2015. Other inclusion
criteria were: age more than 50 years, visual acuity
of hand motion (HM) or better at baseline, and
a follow-up duration of at least one year. All four
physicians used a TAE protocol consisting of initial
intensive monthly anti-VEGF injections until there
was no evidence of exudation on OCT followed
by extension of treatment interval by two weeks
up until 12 weeks. If there was a mild recurrence
of subretinal fluid (SRF), intraretinal fluid (IRF),
or a new macular hemorrhage, then the interval
was reduced by one–two weeks until the macula
was dry or hemorrhage stabilized. In the case
of more severe recurrences, monthly treatment
was reinitiated.[10] The interval was not increased
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in the presence of persistent but stable fluid,
however, if a pigment epithelial detachment (PED)
persisted in the absence of SRF or IRF, then
the interval was extended. Patient demographics,
type of anti-VEGF agent used (bevacizumab,
ranibizumab, or aflibercept), number and frequency
of injections, best-corrected visual acuities (BCVA),
and intraocular pressure (IOP) were obtained at
each office visit from the EDW database. In this
article, single-agent monotherapy is defined as
treatment with only one type of anti-VEGF agent
over the entire treatment course, while multi-agent
therapy is defined as treatment with multiple types
of anti-VEGF agents but not during the same office
visit.
OCT images of the affected eye were obtained
from direct chart review at baseline and at the
last follow-up visit. OCT images of each affected
eye at baseline and the last follow-up visit were
directly reviewed for the presence or absence of
SRF and IRF. BCVA and IOP were extracted for
each affected eye at the start of treatment and at
time-points of six months, one year, and every year
thereafter until the last office visit. Measurements
from the office visit whose date was closest to the
specific time-point were selected but was required
to be within three months of the specific time-
point to be included. Visual acuity values were
converted from Snellen to logMAR to allow the
paired t-test comparisons. Visual acuity values
were also categorized as 20/50 or better, between
20/50 and 20/200, and 20/200 or worse for further
interpretation. The number and types of injections
were also tallied for each affected eye.
Subsequent numerical and statistical analyses
were performed in Microsoft Excel 2016 (Microsoft
Corporation, Redmond, WA) and GraphPad Prism
7 (GraphPad Software, San Diego, CA). The paired
Student T-test was performed to compare visual
acuities and intraocular pressure at the first and
last office visits. Pearson’s correlation coefficient
was calculated to test for the linearity of changes
in visual acuity over time. Statistical analysis was
also performed for visual acuity categories using
contingency tables with Fisher’s exact test and
the OCT data was analyzed with McNemar’s
test. Subgroup analysis was conducted on eyes
treated with single-agent monotherapy to examine
the visual acuity and OCT outcomes for each
drug.
RESULTS
In total, 224 treatment-naïve eyes of 202 patients
were analyzed with an average follow-up period
of 3.4 years (range, 1.0–7.6 years). The majority
(80%) of patients in this study were between 70
and 89 years of age at initial presentation. Of the
224 eyes, 137 (61.2%) were treated with only one
type of anti-VEGF agent: ranibizumab (71, 51.8%),
aflibercept (47, 34.3%), or bevacizumab (19, 13.9%).
Visual acuity at baseline was 20/100 in Snellen and
did not differ significantly between the treatment
groups (F = 1.33, P = 0.27). Most eyes had either
SRF (70%) or IRF (47%) present on OCT imaging at
baseline (Table 1).
The average visual acuity at baseline of 0.698
logMAR (20/100 Snellen equivalent) remained
stable at the final follow-up visit at 0.666 logMAR
(20/93 Snellen) (P = 0.30; Figure 1a). A significant
portion of eyes (40%) maintained their visual
acuities within two Snellen lines, while 34% of eyes
gained more than two lines and 25% lost more
than two lines. The percentage of eyes with visual
acuities of 20/50 or better increased significantly
from 34.8% at baseline to 45.1% by the last follow-
up visit (Fischer’s exact test, P = 0.037; Figure
1b). There was no significant difference between
baseline IOP (14.8 ± 3.3) and IOP at the last follow-
up visit (15.2 ± 3.6) (P = 0.052).
Visual acuities of patients receiving ongoing
injections recorded at six months, one year, and
annually thereafter showed an overall steady gain
that peaks near the end of the third year, with
slight reductions thereafter (Figure 2). The smaller
sample size in these groups impedes any individual
subgroup analysis of the treatment type.
The baseline visual acuity at initial presentation
was tested against the change in visual acuity
along with demographic factors of sex and age
as possible predictors of patient’s response to
treatment. Baseline visual acuities exhibited a
weak linear correlation with the cumulative change
in visual acuities at all time-points (Pearson’s
coefficient r averaged over timepoints = –0.45, P <
0.05). Age was not found to be linearly correlated
with the change in visual acuity at the last follow-up
(Pearson’s r = 0.13, p = 0.33). Similarly, patients’ sex
and also race (Caucasian vs non-Caucasian) were
not correlated with the treatment response (t = –
1.13, P = 0.26 and t = –0.6, P = 0.55, respectively).
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Table 1. Patient baseline characteristics
Monotherapy (N = 137) Multi-drug









Eye – no (%)
OD 7(37) 33 (47) 21 (45) 48 (55) 109 (49)
OS 12(63) 38 (54) 26 (55) 39 (45) 115 (51)
Gender – no (%)
F 16(84) 49 (69) 38 (81) 58 (67) 161 (72)
M 3(16) 22 (31) 9 (19) 29 (33) 63 (28)
Race – no (%)
Caucasian 12(63) 52 (73) 40 (85) 72 (83) 176 (79)
African American 2(11) 4 (6) 0 5 (6) 11 (5)
Hispanic 3(16) 1 (1) 0 2 (2) 6 (3)
Other/Unknown 2(11) 14 (20) 7 (15) 8 (9) 31 (14)
Age
Mean 78.1 ± 12.6 82.1 ± 6.5 83.3 ± 6.4 78.2 ± 8.7 80.5 ± 8.3
50–69 -no. (%) 4 (21) 2 (3) 2 (4) 13 (15) 21 (9)
70–89 -no. (%) 12 (63) 62 (87) 40 (85) 66 (76) 180 (80)
90+ -no. (%) 3 (16) 7 (10) 5 (11) 8 (9) 23 (10)
Visual Acuity (Snellen)
Mean 20/94 20/124 20/91 20/89 20/100
20/50 or Better - no. (%) 7 (37) 19 (27) 20 (43) 32 (37) 78 (35)
Between 20/50 and
20/200 - no. (%)
7 (37) 29 (41) 17 (36) 33 (38) 86 (38)
Worse than 20/200 - no. (%) 5 (26) 23 (32) 10 (21) 22 (25) 60 (27)
OCT Findings
SRF-no. (%) 14 (74) 42 (59) 30 (64) 73 (84) 159 (71)
IRF-no. (%) 8 (42) 43 (61) 27 (57) 28 (32) 106 (47)
OCT, optical coherence tomography; SRF, subretinal fluid; IRF, intraretinal fluid
Over the course of the study, 224 eyes received
an average of 20.3 ± 14.7 injections (range, 2–95)
during a mean of 3.4 years of follow-up (range,
1.0–7.6), for a total of 4,543 injections. Of the 224
eyes, 137 (61.2%) were treated with a single agent
for the duration of their treatment [71 (51.8%) with
ranibizumab, 47 (34.3%) with aflibercept, and 19
(13.9%) with bevacizumab] while 87 (38.8%) eyes
were treated with more than one agent type. For
those patients receiving single-agent therapy, the
number of total injections did not differ significantly
based on the agent used (14.8 for bevacizumab
vs 14.7 for ranibizumab vs 13.0 for aflibercept, P
= 0.54) over the course of treatment, although
the average duration of treatment in weeks varied
significantly (35.5 for bevacizumab vs 28.6 for
ranibizumab vs 21.7 for aflibercept, P = 0.014).
The number of injections that patients received
differed over time (Figure 3). Eyes in the first year
of treatment received an average of 8.4 injections
that decreased on average by 0.3 injections per
year to 5.5 injections by the seventh year (R2 =
0.68). Moreover, eyes that gained more than two
lines received significantly more injections with an
average number of 24.1 ± 15.3 injections, while
eyes that maintained within two lines or lost more
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14 2 P < 0.01 8 2 P = 0.077
Ranibizumab
(N = 71)
42 8 P < 0.001 43 16 P < 0.001
Aflibercept
(N = 47)




73 24 P < 0.001 28 14 P < 0.001
Total Cohort
(N = 224)
159 35 P < 0.001 106 42 P < 0.001
OCT, optical coherence tomography; SRF, subretinal fluid; IRF, intraretinal fluid; VEGF, vascular endothelial growth factor
Figure 1. Comparison of mean visual acuity between baseline and last visit. Figure 1A shows boxplot comparisons between
baseline and final visual acuities. Figure 1B shows the percentage of patients in each visual acuity category by the last follow-up
visit compared to baseline.
than two lines received 18.1 ± 13.3 injections and
18.6 ± 15.2 injections, respectively (P < 0.05). It
was also found that eyes with visual acuities of
20/200 or better at last follow-up tended to receive
treatment over a longer period (average 3.1 years
vs 2.2 years, P < 0.01) and received a greater
number of injections (average 23 vs 14, P < 0.001)
compared to eyes with visual acuities of 20/200 or
worse at last follow-up.
In addition to visual acuity analysis, OCT images
were compared at baseline and at the last follow-
up visit. Out of the 224 eyes, 159 eyes had SRF
at baseline compared with 35 eyes by the date
of last follow-up (P < 0.0001; Figure 4). Similarly,
106 eyes had IRF at baseline compared with 42
eyes by the date of last follow-up (P < 0.0001).
When aggregated, 208 eyes had some type of fluid
at baseline, compared with 69 eyes by the date
of last follow-up (P <0.0001). Subset analysis of
eyes receiving single-agent anti-VEGF therapy did
not reveal any differences in OCT outcomes and
mirrored the trends seen in the overall group. All
treatment groups showed a statistically significant
decrease in the presence of fluid over the course
of the treatment except for the presence of IRF
in the bevacizumab group (Table 2), although this
may be attributed to the smaller sample size of this
subgroup (n = 19).
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Figure 2. Cumulative gain in logMAR over treatment course (Mean ± SE). Visual acuities recorded during patients’ treatment visits
were compared with the visual acuity at baseline. Only those patients actively continuing to receive injections were included in
this figure; patients who discontinued injections after a specific time were not included in subsequent time points in this graph.
Figure 3. Number of injections over time. The figure shows the average annual number of injections administered over time.
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Figure 4. Comparison of OCT finding between baseline and last visit. The figure shows the number of eyes with the presence of
SRF and IRF pre- and post-treatment.
DISCUSSION
We report up to a seven-year (average, 3.4
years) follow-up period of treatment-naïve NV-
AMD patients undergoing anti-VEGF therapy
using a TAE model. All four investigators in our
study used the consensus recommendations of
the TAE regimen following monthly injections
until the macula was dry based on OCT, then
extending the interval between treatments by
two weeks to a maximum of twelve weeks.
If fluid recurred, then the interval would be
shortened. Using this approach, the patients’
treatment is individually tailored to its response.
The TAE regimen offers an alternate and preferred
treatment practice due to reduced burden for
office visits compared to monthly and OCT-guided
dosing regimens.
Prior to the development of TAE regimen, long-
term outcomes of monthly and PRN anti-VEGF
treatments have been described in several other
studies, most notably in the SEVEN-UP and 5-year
CATT study.[13, 14] The SEVEN-UP study reported on
ranibizumab-treated patients after an average of
7.3 years from the time of first injectionwith patients
receiving monthly injections in the first two years
followed by PRN treatment over the subsequent
years. Patients received an average of 6.8 total
injections over a mean 3.4 year interval. The
subgroup that received more frequent injections
yielded a better result in visual acuity gains. In
their study, 23% attained a visual acuity of 20/40 or
better whereas 37% were 20/200 or worse. There
was an overall mean decline of 8.2 letters over the
course of follow-up.[14]
In the five-year CATT study, patients were
followed an average of 5.5 years from the time
of first injection. Ranibizumab- or bevacizumab-
treated patients were stratified into monthly or PRN
arms in the first year with the monthly arm stratified
again into monthly or PRN treatment in the second
year. In the subsequent three years, a variety of
treatment drug combinations and regimens were
used with patients receiving an average of 15.4
injections over three years. In their study, 49.6%
attained visual acuity of 20/40 or better whereas
20% were 20/200 or worse. There was a mean
overall decline of 3.3 letters.[13]
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Since the initial description of the TAE regimen,
several studies have reproduced results favoring
maintenance or improvement of BCVA similar to
monthly dosing while reducing injection frequency
and treatment burden. Our study is comparable
to others that describe outcomes using a TAE
regimen.[18–23] Similar to our study, BCVA in
these studies was either maintained or improved
throughout treatment with 30–34% of patients on
average improving by 2–3 lines and 94–97.5%
patients losing less than 2–3 lines. The number
of injections in the first year averaged a total of
7.6–8.6, which is comparable to our mean of 8.4.
Most of these studies, however, only reported on
outcomes over a two-year follow-upwhile our study
looks at outcomes over a longer treatment period.
Of note, in our study, the average number of
injections decreased to 5.5 during the seventh year
while maintaining BCVA.
A study by Mrejen et al with a longer follow-up
period of six years (average 3.5 years) compared
to the aforementioned studies[18–23] demonstrated
similar favorable results.[10–12] In their study, BCVA
peaked at 18 months with a steady decline
afterward. On average, patients received 28.5
injections over the study period with 8.3 injections
per year and a mean interval of 6.6 weeks between
injections. The majority of their patients (64.3%)
were treated with injection of a single agent of
which 59% of them were ranibizumab alone, 4.3%
were bevacizumab alone, and 1% was aflibercept
alone. Their multivariant analysis showed a greater
number of injections as an independent predictor
of better visual outcomes. On the other hand,
older age of starting injections, hypertension, and
anticoagulation were correlated with poorer visual
outcomes.
In the current study, we utilized a TAE approach
in which patients were followed for an average
of 3.4 years (range, 1.0–7.6) receiving an injection
regimen with an average of 20.3 ± 14.7 total
injections with 8.4 injections in the first year
and 5.5 injections by the seventh year of follow-
up. The majority of patients (61.1%) were treated
with a single anti-VEGF agent for the duration of
their treatment, of which 51.8% were ranibizumab
alone, 34.3% were aflibercept alone, and 13.9%
were bevacizumab alone. Having more single-
agent data analysis allows us to validate similarities
of BCVA outcomes regardless of the drug type.
BCVA peaked after three years of treatment with
a slow decline thereafter. Baseline visual acuity
was weakly shown to be the only significant
predictor of change in visual acuity. There were
no significant differences between drug type and
visual acuity effect, number of injections needed,
or OCT outcomes.
Eyes with a final visual acuity of 20/50 or better
increased from 34.8% at the beginning of the
study to 45.1% at the latest follow-up (P = 0.037),
while eyes with 20/200 or worse remained stable
at 26.8% at baseline compared to 27.7% at last
follow-up (p = 0.92). In contrast, in the five-year
CATT study, eyes with 20/200 or worse increased
significantly from 6% at baseline to 20% at the last
follow-up[13] even though in our study there were
more patients with baseline vision of 20/200 or
worse. At the end of the SEVEN-UP study, 37%
of patients were reported to have visual acuity of
20/200 or worse. Overall, 74% of patients in our
study maintained or gained at least two Snellen
lines of visual acuity, compared with the SEVEN-
UP trial where only 55% of eyes maintained or
improved their vision.[14] At the end of our study,
eyes that improved by at least two lines received
an average of 24 injections, while all other eyes
received an average of 18 injections. Similarly,
in the SEVEN-UP study, eyes receiving a greater
number of injections (11 vs 6.8) gained 3.9 letters
overall and were more likely to show improvement
in vision.[14]
The better visual outcomes in our population
compared to the five-year CATT study may be
explained by the OCT analysis. At the last follow-up
visit, 16% of eyes in our study had SRF and 19% of
eyes had IRF. Those without SRF or IRF had either
a PED or were without any fluid. In comparison,
at the end of five years in the CATT study, 38%
had SRF and 61% had IRF.[13] Eyes with residual
IRF yield worse visual outcomes compared with
eyes with residual SRF or absence of fluid.[16] More
frequent treatments may have an impact on the
amount of fluid on OCT to allow for maintenance
or gain in visual acuity. However, other factors
such as geographic atrophy also contribute to
the final visual acuity. Though not studied in our
population, the CATT study demonstrated that 24%
of eyes with monthly dosing showed geographic
atrophy compared to 15% in the PRN group.
Similarly, in the IVAN trial, 34% versus 26% showed
progressive atrophy in the monthly versus PRN
groups, respectively.[8, 13, 17]
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Our study demonstrates that a TAEmodel allows
for a frequent albeit lower treatment burden as
compared to monthly dosing with reduction in fluid
on OCT. This may theoretically lower the rate of
geographic atrophy while maintaining similar gains
in visual potential compared with a monthly dosing
regimen.
There are several limitations in our study most
notably its retrospective nature. With data being
compiled via electronic database, records may
be incomplete and there may be innate errors
in how the data was recorded. Patients began
treatment at different times between 2008 and
2015 and there may be differences both in medical
technology and in practice patterns amongst
providers. There is no monthly regimen treatment
arm to compare its efficacy with our TAE model.
Due to the method of data collection, there
were fewer patients with more than four to five
years of treatment available for analysis thereby
limiting sample size and comparisons across
different anti-VEGF agents. Some patients have
undergone cataract surgery during treatment
period, which can confound BCVA amongst
patients. Furthermore, more in-depth studies are
needed to analyze the impact of residual fluid type
on visual acuity.
In conclusion, our retrospective uncontrolled
review of a large urban cohort of NV-AMD reveals
favorable long-term visual and anatomic results
of anti-VEGF therapy using a TAE regimen. Our
study demonstrates that visual acuity seems to
improve with more frequent injections over a
longer period of time. Themajority of patients (74%)
maintained or improved vision with 45% of patients
achieving VA of 20/50 or better at their last follow-
up over a seven-year period. Our study supports
the use of a TAE treatment paradigm to reduce
both office visits and treatment burden while
still achieving positive functional and anatomic
results.
Financial Support and Sponsorship
This study was supported in part by an unrestricted
grant from Research to Prevent Blindness and
by the Northwestern Medicine Enterprise Data
Warehouse. The sponsor or funding organization
had no role in the design or conduct of this
research.
Conflicts of Interest
There are no conflicts of interest.
REFERENCES
1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK,
Chung CY, et al. Ranibizumab for neovascular age-related
macular degeneration. New Engl J Med 2006;355:1419–
1431.
2. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels
S, Feuer W, et al. A variable-dosing regimen with
intravitreal ranibizumab for neovascular age-related
macular degeneration: year 2 of the PrONTO Study. Am J
Ophthalmol 2009;148:43–58e1.
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP,
Ianchulev T, et al. Ranibizumab versus verteporfin
photodynamic therapy for neovascular age-related
macular degeneration: two-year results of the ANCHOR
study. Ophthalmology 2009;116:57–65e5.
4. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK,
Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye)
in wet age-related macular degeneration. Ophthalmology
2012;119:2537–2548.
5. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM,
Chong V, Nguyen QD, et al. Intravitreal aflibercept
injection for neovascular age-related macular
degeneration: ninety-six-week results of the VIEW
studies. Ophthalmology 2014;121:193–201.
6. Investigators IS, Chakravarthy U, Harding SP, Rogers
CA, Downes SM, Lotery AJ, et al. Ranibizumab
versus bevacizumab to treat neovascular age-related
macular degeneration: one-year findings from the IVAN
randomized trial. Ophthalmology 2012;119:1399–1411.
7. Comparison of Age-related Macular Degeneration
Treatments Trials Research G, Martin DF, Maguire MG,
Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and
bevacizumab for treatment of neovascular age-related
macular degeneration: two-year results. Ophthalmology
2012;119:1388–1398.
8. Chakravarthy U, Harding SP, Rogers CA, Downes SM,
Lotery AJ, Culliford LA, et al. Alternative treatments to
inhibit VEGF in age-related choroidal neovascularisation:
2-year findings of the IVAN randomised controlled trial.
Lancet 2013;382:1258–1267.
9. Engelbert M, Zweifel SA, Freund KB. ”Treat and extend”
dosing of intravitreal antivascular endothelial growth factor
therapy for type 3 neovascularization/retinal angiomatous
proliferation. Retina 2009;29:1424–1431.
10. Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic
J, Herbert E, et al. Treat-and-extend regiments with anti-
VEGF agents in retinal diseases: a literature review and
consensus recommendations. Retina 2015;35:1489–1506.
11. Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer
RH, Hunyor AP, et al. Two-year outcomes of ”treat and
extend” intravitreal therapy for neovascular age-related
macular degeneration. Ophthalmology 2015;122:1212–
1219.
12. Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R,
Yannuzzi N, et al. Long-term visual outcomes for a treat and
JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 3, JULY-SEPTEMBER 2020 339
Treat and Extend Anti-VEGF Regimens; Lee et al
extend anti-Vascular Endothelial Growth Factor regimen in
eyes with neovascular age-related macular degeneration.
J Clin Med 2015;4:1380–1402.
13. Comparison of Age-related Macular Degeneration
Treatments Trials Research G, Maguire MG, Martin DF,
Ying GS, Jaffe GJ, Daniel E, et al. Five-year outcomes
with anti-Vascular Endothelial Growth Factor treatment
of neovascular age-related macular degeneration:
the comparison of age-related macular degeneration
treatments trials. Ophthalmology 2016;123:1751–1761.
14. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang
K, Group S-US. Seven-year outcomes in ranibizumab-
treated patients in ANCHOR, MARINA, and HORIZON:
a multicenter cohort study (SEVEN-UP). Ophthalmology
2013;120:2292–2299.
15. Calvo P, Wang Y, Ferreras A, Lam WC, Denevyl R,
Brent M. Treat and extend versus treat and observe in
wet age-related macular degeneration patients treated
with ranibizumab: 3-year surveillance period. J Clin Exp
Ophthalmol 2014;5:1–5.
16. Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I,
Bonicel P, et al. Inject and extend dosing versus dosing as
needed: a comparative retrospective study of ranibizumab
in exudative age-related macular degeneration. Retina
2011;1:26–30.
17. Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer
RH. Anti-VEGF treatment in neovascular age-related
macular degeneration: a treat-and-extend protocol over 2
years. Retina 2014;34:1531–1538.
18. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS,
Regillo CD. A treat and extend regimen using ranibizumab
for neovascular age-related macular degeneration clinical
and economic impact. Ophthalmology 2010;117:2134–
2140.
19. Rayess N, Houston SK, 3rd, Gupta OP, Ho AC, Regillo
CD. Treatment outcomes after 3 years in neovascular age-
related macular degeneration using a treat-and-extend
regimen. Am J Ophthalmol 2015;159:3–8e1.
20. Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser
RS, Regillo CD. Bevacizumab for neovascular age-
related macular degeneration using a treat-and-extend
regimen: clinical and economic impact. Am J Ophthalmol
2012;153:468–473e1.
21. DeCroos FC, Reed D, Adam MK, Salz D, Gupta OP,
Ho AC, et al. Treat-and-extend therapy using aflibercept
for neovascular age-related macular degeneration: a
prospective clinical trial. Am J Ophthalmol 2017;180:142–
150.
22. Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne
JF, et al. Randomized trial of treat-and-extend versus
monthly dosing for neovascular age-related macular
degeneration. Ophthalmol Retina 2017;1:314–321.
23. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG,
Ying GS, et al. Macular morphology and visual acuity
in the comparison of age-related macular degeneration
treatments trials. Ophthalmology 2013;120:1860–1870.
24. Holz FG, Tuomi L, Ding B, Hopkins JJ. Development of
atrophy in neovascular AMD treated with ranibizumab in
the HARBOR study. Invest Ophthalmol Vis Sci 2015;56.
ARVO E-Abstract 890.
340 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 3, JULY-SEPTEMBER 2020
